Understanding and treating rare viral infections in newborns
Official title: Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium (RDCRC)
Funded at University of Alabama at Birmingham · NIH-10915383 · Data updated 2026-11-12
This study is working to improve care and treatment options for babies born with viral infections like CMV and herpes by bringing together 28 research sites to share knowledge and find better therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | September 1, 2019 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,408,997 |
| NIH project number | 5U54AI150225-05 |
| Project ID | NIH-10915383 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation are infants under 2 years old diagnosed with congenital or perinatal viral infections.
✕Less likely to help
Patients with viral infections not classified as congenital or perinatal may not receive benefit from this research.
What this research studies
This research focuses on congenital and perinatal viral infections, such as congenital cytomegalovirus (CMV) disease and neonatal herpes simplex virus (HSV) infection. The project aims to build a collaborative network of 28 study sites to enhance clinical trial readiness and improve patient care for affected infants. By leveraging long-standing partnerships and advanced data coordination, the research seeks to identify effective therapies and reduce the burden of these rare diseases. Patients may benefit from improved treatment options and better understanding of their conditions.
Why it matters
Potential benefit: If successful, this research could lead to improved therapies and care for infants suffering from rare viral infections.
How similar studies have gone: Previous research has shown success in collaborative approaches to studying rare diseases, indicating potential for impactful findings in this area.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Kimberlin, David W — University of Alabama at Birmingham
- Study coordinator: Kimberlin, David W
Related research
Other NIH-funded projects on the same topics.
-
Liver pathobiology from rare liver diseases
A study at UCSF looks at why rare liver conditions cause liver damage, with the aim of finding new ways to diagnose and treat chronic liver disease.
-
Data Management and Coordinating Center support for Rare Diseases Research
A national rare diseases research program is funding a center to manage data and coordinate studies to help improve diagnosis, care, and potential treatments for children with rare conditions.
-
EEG-based drug repurposing for rare CNS diseases
A new approach uses EEG brain signatures to find existing drugs that might help people with rare nervous-system disorders.
-
Ethics of Engaging Patient Groups in Drug Development for Rare Diseases
This grant asks how patient and family groups can ethically help shape rare-disease drug development from idea to market, with input from patients, families, doctors, and researchers.
-
Center for Polyamine Disorders group study of rare metabolic disorders
A research consortium is studying a group of rare metabolic disorders linked to polyamines and aims to understand symptoms, biomarkers, and disease progression to improve care.
-
Encore: speeding up finding new uses for existing drugs to help kids with rare diseases
A big NIH project will test thousands of existing medicines to see if any can help treat rare genetic diseases in children.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.